To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery

被引:2076
作者
Danhier, Fabienne [1 ]
Feron, Olivier [2 ]
Preat, Veronique [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Unite Pharm Galen, UCL FARG 7320, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Inst Expt & Clin Res, B-1200 Brussels, Belgium
关键词
Active targeting; Passive targeting; Enhanced Permeability and Retention effect; Nanocarriers; ALBUMIN-BOUND PACLITAXEL; IN-VIVO; MAGNETIC NANOPARTICLES; FOLATE-RECEPTOR; CANCER-CELLS; PHARMACEUTICAL NANOCARRIERS; INTRACELLULAR DELIVERY; LIPOSOMAL CHEMOTHERAPY; THERAPEUTIC AGENTS; ANTITUMOR-ACTIVITY;
D O I
10.1016/j.jconrel.2010.08.027
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Because of the particular characteristics of the tumor microenvironment and tumor angiogenesis, it is possible to design drug delivery systems that specifically target anti-cancer drugs to tumors. Most of the conventional chemotherapeutic agents have poor pharmacokinetics profiles and are distributed non-specifically in the body leading to systemic toxicity associated with serious side effects. Therefore, the development of drug delivery systems able to target the tumor site is becoming a real challenge that is currently addressed. Nanomedicine can reach tumor passively through the leaky vasculature surrounding the tumors by the Enhanced Permeability and Retention effect whereas ligands grafted at the surface of nanocarriers allow active targeting by binding to the receptors overexpressed by cancer cells or angiogenic endothelial cells. This review is divided into two parts: the first one describes the tumor microenvironment and the second one focuses on the exploitation and the understanding of these characteristics to design new drug delivery systems targeting the tumor. Delivery of conventional chemotherapeutic anti-cancer drugs is mainly discussed. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:135 / 146
页数:12
相关论文
共 112 条
[1]   Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy [J].
Acharya, Sarbari ;
Dilnawaz, Fahima ;
Sahoo, Sanjeeb K. .
BIOMATERIALS, 2009, 30 (29) :5737-5750
[2]  
Adams GP, 2001, CANCER RES, V61, P4750
[3]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[4]   Integrins in angiogenesis and lymphangiogenesis [J].
Avraamides, Christie J. ;
Garmy-Susini, Barbara ;
Varner, Judith A. .
NATURE REVIEWS CANCER, 2008, 8 (08) :604-617
[5]   Drug targeting and tumor heterogeneity [J].
Bae, You Han .
JOURNAL OF CONTROLLED RELEASE, 2009, 133 (01) :2-3
[6]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[7]   Intracellular delivery of nanopartides via the HIV-1 tat pepticle [J].
Berry, C. C. .
NANOMEDICINE, 2008, 3 (03) :357-365
[8]   Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery [J].
Bouzin, Caroline ;
Feron, Olivier .
DRUG RESISTANCE UPDATES, 2007, 10 (03) :109-120
[9]   Oxygen, a source of life and stress [J].
Brahimi-Horn, M. Christiane ;
Pouyssegur, Jacques .
FEBS LETTERS, 2007, 581 (19) :3582-3591
[10]   Active targeting schemes for nanoparticle systems in cancer therapeutics [J].
Byrne, James D. ;
Betancourt, Tania ;
Brannon-Peppas, Lisa .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (15) :1615-1626